Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

The United States accounted for the highest market size of MCI, approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets, i.e., EU4 countries (Germany, ...

Patients with iRBD showed decreased GMV in the prefrontal cortices, temporal lobe, and caudate, and increased cerebellar and thalamic GMV.

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III ...

LBT-3627 is under clinical development by Longevity Biotech and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease ha ...

Discover the surprising link between herpes and Alzheimer's disease. Find out how the common herpes simplex virus may play a ...

"In people with progressive cognitive decline, the diagnosis of Alzheimer's disease requires a demonstration of amyloid and ...

ION-464 is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Parkinson's Disease.

Stem cells offer new treatments for Parkinsons, diabetes, and epilepsy by 2025 Stem cells revolutionize possibilities for ...

Half a million people in the U.S. have been diagnosed with Parkinson's disease. Parkinson's disease is known for the tremors that it causes, but about half of patients experiencing the disease ...